Date: 2017-08-14
Type of information: Research agreement
Compound:
Company: Aduro Biotech (USA - CA) HitGen (China)
Therapeutic area: undisclosed
Type agreement: research
Action mechanism:
Disease:
Details:
- • On August 14, 2017, HitGen announced that the company has entered into a multi-target multi-year collaboration with Aduro Biotech, to discover novel small molecule leads for multiple therapeutic targets of interest to Aduro. According to the agreement, HitGen will use its advanced technology platform, based on DNA-encoded library (DEL) design, synthesis and screening to discover novel leads which will be licensed exclusively to Aduro.
- HitGen is a biotech company with headquarters and main research facilities based in Chengdu, China and with laboratory in Houston. HitGen has established a DNA encoded chemical libraries (DELs) that contain more than 85 billion novel, diverse, drug-like compounds. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed with tractable chemistry and proven results for finding drug leads against targets from known and novel protein classes.
Financial terms:
- Under the terms of the agreement, HitGen will receive an upfront payment and be eligible for milestone payments from Aduro.
Latest news:
Is general: Yes
